GRAIL (NASDAQ:GRAL) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS

GRAIL (NASDAQ:GRAL) released its quarterly earnings results on Wednesday. The company reported ($2.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.66) by $0.10, FiscalAI reports. The business had revenue of $44.69 million during the quarter, compared to analyst estimates of $42.39 million. GRAIL had a negative return on equity of 16.05% and a negative net margin of 236.95%.

Here are the key takeaways from GRAIL’s conference call:

• Galleri sales continued to grow: Second-quarter screening revenue rose 24% year over year to $42.6 million, while test volume increased 35% to more than 61,000. The company added approximately 1,000 ordering providers and said growth is coming from brick-and-mortar physicians, digital health partners, employers, and payer partnerships.
• FDA review remains on track: GRAIL expects an FDA advisory committee meeting in fall 2026 and continues to anticipate potential approval in the first part of 2027. Management said the PMA review is progressing through an iterative process and that it is preparing for the advisory committee.
• Clinical data showed strong detection and safety metrics: Management highlighted false-positive rates below 0.5%, positive predictive values of 50% to 60%, and substantially higher cancer detection when Galleri was added to standard screening. The company also emphasized that roughly 40% to 50% of detected cancers were stage I or II, although the NHS-Galleri trial did not meet its primary endpoint for reducing stage III and IV cancers.
• Samsung financing supports international expansion: GRAIL completed a $110 million strategic investment from Samsung and began planning commercialization in South Korea, with potential expansion to Japan and Singapore. Management said discussions around distribution and longer-term collaboration are just beginning.
• Investment and pricing pressures remain: Adjusted EBITDA loss widened 15% year over year to $90.3 million, while average selling price declined because of greater digital-health volume and lower employer pricing. An Illumina royalty expected to resume toward the end of the fourth quarter will also create a future margin headwind, though management expects minimal Q4 impact.

GRAIL Trading Up 9.6%

NASDAQ GRAL traded up $6.08 during trading on Friday, reaching $69.48. 1,638,967 shares of the company’s stock were exchanged, compared to its average volume of 937,263. GRAIL has a fifty-two week low of $29.95 and a fifty-two week high of $118.84. The company’s fifty day simple moving average is $66.76 and its 200-day simple moving average is $66.48. The firm has a market capitalization of $2.98 billion, a PE ratio of -7.13 and a beta of 3.24.

Insider Buying and Selling at GRAIL

In other news, insider Andrew John Partridge sold 1,491 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $61.08, for a total value of $91,070.28. Following the completion of the sale, the insider directly owned 163,738 shares of the company’s stock, valued at $10,001,117.04. This represents a 0.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.83% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in GRAL. Comerica Bank lifted its position in GRAIL by 59.2% in the 3rd quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after buying an additional 173 shares in the last quarter. Intesa Sanpaolo S.p.A. purchased a new position in shares of GRAIL during the 4th quarter valued at $44,000. Ankerstar Wealth LLC purchased a new position in shares of GRAIL during the 4th quarter valued at $45,000. Rossby Financial LCC increased its stake in shares of GRAIL by 25.0% in the fourth quarter. Rossby Financial LCC now owns 1,250 shares of the company’s stock worth $107,000 after acquiring an additional 250 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its stake in shares of GRAIL by 244.0% in the third quarter. CIBC Private Wealth Group LLC now owns 1,610 shares of the company’s stock worth $95,000 after acquiring an additional 1,142 shares during the last quarter.

Analysts Set New Price Targets

GRAL has been the subject of a number of analyst reports. Piper Sandler upped their price objective on shares of GRAIL from $54.00 to $56.00 and gave the company a “neutral” rating in a research note on Wednesday, May 6th. Mizuho lifted their target price on shares of GRAIL from $58.00 to $65.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 15th. Wall Street Zen upgraded shares of GRAIL from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. TD Cowen restated a “buy” rating on shares of GRAIL in a report on Wednesday, July 15th. Finally, The Goldman Sachs Group started coverage on shares of GRAIL in a research report on Friday, June 5th. They issued a “neutral” rating and a $60.00 price target for the company. Four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $67.78.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.